EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome

被引：11

作者：

Tiefenbacher, Andreas ^{[1
]}

Pirker, Robert ^{[1
]}

机构：

[1] Med Univ Vienna, Dept Med 1, Wahringer Gurtel 18-20, A-1090 Vienna, Austria

来源：

JOURNAL OF THORACIC DISEASE | 2017年 / 9卷 / 11期

关键词：

CHEMOTHERAPY PLUS CETUXIMAB; PHASE-III TRIAL; OPEN-LABEL; BEVACIZUMAB; GROWTH; OSIMERTINIB; MULTICENTER; GEMCITABINE; CISPLATIN; ERLOTINIB;

D O I：

10.21037/jtd.2017.10.02

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页码：4208 / 4211

页数：4

共 19 条

[11] Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial [J].

Pirker, Robert ;

Pereira, Jose R. ;

Szczesna, Aleksandra ;

von Pawel, Joachim ;

Krzakowski, Maciej ;

Ramlau, Rodryg ;

Vynnychenko, Ihor ;

Park, Keunchil ;

Yu, Chih-Teng ;

Ganul, Valentyn ;

Roh, Jae-Kyung ;

Bajetta, Emilio ;

O'Byrne, Kenneth ;

de Marinis, Filippo ;

Eberhardt, Wilfried ;

Goddemeier, Thomas ;

Emig, Michael ;

Gatzemeier, Ulrich ;

Pirker, R. ;

Thatcher, N. ;

Armand, J. P. ;

Camus, P. ;

Victor, N. ;

Emig, M. ;

Mueser, M. ;

Pilz, K. ;

Goddemeier, T. ;

Montaner, I. ;

Lachs, Martin ;

Hoang-Sayag, Loan ;

Alvarez, A. ;

Coppola, F. ;

Recondo, G. ;

Richardet, E. ;

Kirsten, F. ;

Karapetis, C. ;

Parente, P. ;

Michael, M. ;

White, S. ;

Boyce, A. ;

Lewis, C. ;

Slancar, M. ;

Pavlakis, N. ;

Abdi, E. ;

Underhill, C. ;

Pittman, K. ;

Burghuber, O. ;

Pirker, R. ;

Ruckser, R. ;

Ulsperger, E. .

LANCET, 2009, 373 (9674) :1525-1531

[12] Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer [J].

Pujol, Jean-Louis ;

Pirker, Robert ;

Lynch, Thomas J. ;

Butts, Charles A. ;

Rosell, Rafael ;

Shepherd, Frances A. ;

Vansteenkiste, Johan ;

O'Byrne, Kenneth J. ;

de Blas, Barbara ;

Heighway, Jim ;

von Heydebreck, Anja ;

Thatcher, Nick .

LUNG CANCER, 2014, 83 (02) :211-218

[13]

Ramalingam S, 2017, ANN ONCOL, V28

[14] Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL [J].

Reck, Martin ;

von Pawel, Joachim ;

Zatloukal, Petr ;

Ramlau, Rodryg ;

Gorbounova, Vera ;

Hirsh, Vera ;

Leighl, Natasha ;

Mezger, Joerg ;

Archer, Venice ;

Moore, Nicola ;

Manegold, Christian .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1227-1234

[15] Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial [J].

Rosell, Rafael ;

Dafni, Urania ;

Felip, Enriqueta ;

Curioni-Fontecedro, Alessandra ;

Gautschi, Oliver ;

Peters, Solange ;

Massuti, Bartomeu ;

Palmero, Ramon ;

Ponce Aix, Santiago ;

Carcereny, Enric ;

Frueh, Martin ;

Pless, Miklos ;

Popat, Sanjay ;

Kotsakis, Athanasios ;

Cuffe, Sinead ;

Bidoli, Paolo ;

Favaretto, Adolfo ;

Froesch, Patrizia ;

Reguart, Noemi ;

Puente, Javier ;

Coate, Linda ;

Barlesi, Fabrice ;

Rauch, Daniel ;

Thomas, Michael ;

Camps, Carlos ;

Gomez-Codina, Jose ;

Majem, Margarita ;

Porta, Rut ;

Shah, Riyaz ;

Hanrahan, Emer ;

Kammler, Roswitha ;

Ruepp, Barbara ;

Rabaglio, Manuela ;

Kassapian, Marie ;

Karachaliou, Niki ;

Tam, Rachel ;

Shames, David S. ;

Molina-Vila, Miguel A. ;

Stahel, Rolf A. .

LANCET RESPIRATORY MEDICINE, 2017, 5 (05) :435-444

[16] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [J].

Sandler, Alan ;

Gray, Robert ;

Perry, Michael C. ;

Brahmer, Julie ;

Schiller, Joan H. ;

Dowlati, Afshin ;

Lilenbaum, Rogerio ;

Johnson, David H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) :2542-2550

[17] Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study [J].

Seto, Takashi ;

Kato, Terufumi ;

Nishio, Makoto ;

Goto, Koichi ;

Atagi, Shinji ;

Hosomi, Yukio ;

Yamamoto, Noboru ;

Hida, Toyoaki ;

Maemondo, Makoto ;

Nakagawa, Kazuhiko ;

Nagase, Seisuke ;

Okamoto, Isamu ;

Yamanaka, Takeharu ;

Tajima, Kosei ;

Harada, Ryosuke ;

Fukuoka, Masahiro ;

Yamamoto, Nobuyuki .

LANCET ONCOLOGY, 2014, 15 (11) :1236-1244

[18] Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial [J].

Thatcher, Nick ;

Hirsch, Fred R. ;

Luft, Alexander V. ;

Szczesna, Aleksandro ;

Ciuleanu, Tudor E. ;

Dediu, Mircea ;

Ramlau, Rodryg ;

Galiulin, Rinat K. ;

Balint, Beatrix ;

Losonczy, Gyoergy ;

Kazarnowicz, Andrzej ;

Park, Keunchil ;

Schumann, Christian ;

Reck, Martin ;

Depenbrock, Henrik ;

Nanda, Shivani ;

Letunic, Anamarija Kruljac ;

Kurek, Raffacl ;

Paz-Ares, Luis ;

Socinskf, Mark A. .

LANCET ONCOLOGY, 2015, 16 (07) :763-774

[19] Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway [J].

Wei, LH ;

Kuo, ML ;

Chen, CA ;

Chou, CH ;

Lai, KB ;

Lee, CN ;

Hsieh, CY .

ONCOGENE, 2003, 22 (10) :1517-1527

← 1 2 →